Literature DB >> 30262514

Production and Use of the First-Row Transition Metal PET Radionuclides 43,44Sc, 52Mn, and 45Ti.

Ivis F Chaple1, Suzanne E Lapi2.   

Abstract

With the increasing focus on a more personalized approach to medicine using imaging techniques to select patients for targeted treatment or theranostic strategies, interest in the development of new radionuclides is expanding. Through the development of production and radiochemistry techniques, several new radiometals are being added to the toolbox of the nuclear imaging community. 43,44g,mSc, 52gMn, and 45Ti are all emerging transition metal radionuclides and will be discussed in this short review. Each of these nuclides has unique imaging characteristics and shows promise for the development of new molecular imaging agents.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  isotope production; manganese-52; positron emission tomography; scandium-43; scandium-44; titanium-45

Mesh:

Substances:

Year:  2018        PMID: 30262514     DOI: 10.2967/jnumed.118.213264

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

1.  Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets.

Authors:  Alexandra I Fonseca; Vítor H Alves; Sérgio J C do Carmo; Magda Silva; Ivanna Hrynchak; Francisco Alves; Amílcar Falcão; Antero J Abrunhosa
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-07

Review 2.  Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Authors:  K J H George; S Borjian; M C Cross; J W Hicks; P Schaffer; M S Kovacs
Journal:  RSC Adv       Date:  2021-09-21       Impact factor: 4.036

3.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

4.  Synthesis, radiolabeling, and pre-clinical evaluation of [44Sc]Sc-AAZTA conjugate PSMA inhibitor, a new tracer for high-efficiency imaging of prostate cancer.

Authors:  S Ghiani; I Hawala; D Szikra; G Trencsényi; Z Baranyai; G Nagy; A Vágner; R Stefania; S Pandey; A Maiocchi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-09       Impact factor: 9.236

Review 5.  Manganese in PET imaging: Opportunities and challenges.

Authors:  Marie Brandt; Jens Cardinale; Ivo Rausch; Thomas L Mindt
Journal:  J Labelled Comp Radiopharm       Date:  2019-06-30       Impact factor: 1.921

6.  Design, Synthesis, Computational, and Preclinical Evaluation of natTi/45Ti-Labeled Urea-Based Glutamate PSMA Ligand.

Authors:  Kristina Søborg Pedersen; Christina Baun; Karin Michaelsen Nielsen; Helge Thisgaard; Andreas Ingemann Jensen; Fedor Zhuravlev
Journal:  Molecules       Date:  2020-03-02       Impact factor: 4.411

Review 7.  The chemical tool-kit for molecular imaging with radionuclides in the age of targeted and immune therapy.

Authors:  Timothy H Witney; Philip J Blower
Journal:  Cancer Imaging       Date:  2021-01-30       Impact factor: 3.909

Review 8.  Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.

Authors:  R Mikolajczak; S Huclier-Markai; C Alliot; F Haddad; D Szikra; V Forgacs; P Garnuszek
Journal:  EJNMMI Radiopharm Chem       Date:  2021-05-25

9.  Characterization of actinide resin for separation of 51,52gMn from bulk target material.

Authors:  Kendall E Barrett; Eduardo Aluicio-Sarduy; Steffen Happel; Aeli P Olson; Christopher J Kutyreff; Paul A Ellison; Todd E Barnhart; Jonathan W Engle
Journal:  Nucl Med Biol       Date:  2021-03-03       Impact factor: 2.408

10.  Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44.

Authors:  Brett A Vaughn; Shin Hye Ahn; Eduardo Aluicio-Sarduy; Justin Devaraj; Aeli P Olson; Jonathan Engle; Eszter Boros
Journal:  Chem Sci       Date:  2019-11-20       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.